Alfimeprase, a plasminogen-independent thrombolytic

Amit R. Shah, Larry A. Scher

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Alfimeprase is an analog of a fibrolase that disrupts formed thrombi through the hydrolysis of fibrin, rather than by activation of plasminogen. Nuvelo Inc, under license from Amgen Inc and together with Bayer AG, is developing this thrombolytic for the potential intravenous treatment of peripheral arterial occlusions and for other cardiovascular indications. Pharmacokinetic studies showed that alfimeprase was rapidly absorbed and achieved therapeutic concentrations at relatively low doses. Preclinical studies showed that adjunctive therapy with antiplatelet agents was necessary to maintain luminal patency. In phase I and II clinical trials alfimeprase effectively thombolysed clots with no drug-related adverse events. However, phase III clinical trials of alfimeprase did not meet their primary endpoints and enrollment in ongoing trials has been suspended pending further analyses and discussion with outside experts and regulatory agencies. In spite of this, the authors conclude that alfimeprase seems to be a lytic agent with much potential. Refinement in its use and dosing needs to be addressed, and further investigation into its pharmacokinetic properties may be worthwhile. Alfimeprase is a drug that is a 'work in progress'.

Original languageEnglish (US)
Pages (from-to)329-335
Number of pages7
JournalIDrugs
Volume10
Issue number5
StatePublished - May 2007

Fingerprint

Plasminogen
Pharmacokinetics
Phase III Clinical Trials
Phase II Clinical Trials
Clinical Trials, Phase I
Platelet Aggregation Inhibitors
Licensure
Drug-Related Side Effects and Adverse Reactions
Fibrin
alfimeprase
Thrombosis
Hydrolysis
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Alfimeprase, a plasminogen-independent thrombolytic. / Shah, Amit R.; Scher, Larry A.

In: IDrugs, Vol. 10, No. 5, 05.2007, p. 329-335.

Research output: Contribution to journalArticle

Shah, AR & Scher, LA 2007, 'Alfimeprase, a plasminogen-independent thrombolytic', IDrugs, vol. 10, no. 5, pp. 329-335.
Shah, Amit R. ; Scher, Larry A. / Alfimeprase, a plasminogen-independent thrombolytic. In: IDrugs. 2007 ; Vol. 10, No. 5. pp. 329-335.
@article{9a3e411a7cf64a229571063050d7f26f,
title = "Alfimeprase, a plasminogen-independent thrombolytic",
abstract = "Alfimeprase is an analog of a fibrolase that disrupts formed thrombi through the hydrolysis of fibrin, rather than by activation of plasminogen. Nuvelo Inc, under license from Amgen Inc and together with Bayer AG, is developing this thrombolytic for the potential intravenous treatment of peripheral arterial occlusions and for other cardiovascular indications. Pharmacokinetic studies showed that alfimeprase was rapidly absorbed and achieved therapeutic concentrations at relatively low doses. Preclinical studies showed that adjunctive therapy with antiplatelet agents was necessary to maintain luminal patency. In phase I and II clinical trials alfimeprase effectively thombolysed clots with no drug-related adverse events. However, phase III clinical trials of alfimeprase did not meet their primary endpoints and enrollment in ongoing trials has been suspended pending further analyses and discussion with outside experts and regulatory agencies. In spite of this, the authors conclude that alfimeprase seems to be a lytic agent with much potential. Refinement in its use and dosing needs to be addressed, and further investigation into its pharmacokinetic properties may be worthwhile. Alfimeprase is a drug that is a 'work in progress'.",
author = "Shah, {Amit R.} and Scher, {Larry A.}",
year = "2007",
month = "5",
language = "English (US)",
volume = "10",
pages = "329--335",
journal = "IDrugs : the investigational drugs journal",
issn = "1369-7056",
publisher = "Current Drugs Ltd.",
number = "5",

}

TY - JOUR

T1 - Alfimeprase, a plasminogen-independent thrombolytic

AU - Shah, Amit R.

AU - Scher, Larry A.

PY - 2007/5

Y1 - 2007/5

N2 - Alfimeprase is an analog of a fibrolase that disrupts formed thrombi through the hydrolysis of fibrin, rather than by activation of plasminogen. Nuvelo Inc, under license from Amgen Inc and together with Bayer AG, is developing this thrombolytic for the potential intravenous treatment of peripheral arterial occlusions and for other cardiovascular indications. Pharmacokinetic studies showed that alfimeprase was rapidly absorbed and achieved therapeutic concentrations at relatively low doses. Preclinical studies showed that adjunctive therapy with antiplatelet agents was necessary to maintain luminal patency. In phase I and II clinical trials alfimeprase effectively thombolysed clots with no drug-related adverse events. However, phase III clinical trials of alfimeprase did not meet their primary endpoints and enrollment in ongoing trials has been suspended pending further analyses and discussion with outside experts and regulatory agencies. In spite of this, the authors conclude that alfimeprase seems to be a lytic agent with much potential. Refinement in its use and dosing needs to be addressed, and further investigation into its pharmacokinetic properties may be worthwhile. Alfimeprase is a drug that is a 'work in progress'.

AB - Alfimeprase is an analog of a fibrolase that disrupts formed thrombi through the hydrolysis of fibrin, rather than by activation of plasminogen. Nuvelo Inc, under license from Amgen Inc and together with Bayer AG, is developing this thrombolytic for the potential intravenous treatment of peripheral arterial occlusions and for other cardiovascular indications. Pharmacokinetic studies showed that alfimeprase was rapidly absorbed and achieved therapeutic concentrations at relatively low doses. Preclinical studies showed that adjunctive therapy with antiplatelet agents was necessary to maintain luminal patency. In phase I and II clinical trials alfimeprase effectively thombolysed clots with no drug-related adverse events. However, phase III clinical trials of alfimeprase did not meet their primary endpoints and enrollment in ongoing trials has been suspended pending further analyses and discussion with outside experts and regulatory agencies. In spite of this, the authors conclude that alfimeprase seems to be a lytic agent with much potential. Refinement in its use and dosing needs to be addressed, and further investigation into its pharmacokinetic properties may be worthwhile. Alfimeprase is a drug that is a 'work in progress'.

UR - http://www.scopus.com/inward/record.url?scp=34247594281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247594281&partnerID=8YFLogxK

M3 - Article

C2 - 17487785

AN - SCOPUS:34247594281

VL - 10

SP - 329

EP - 335

JO - IDrugs : the investigational drugs journal

JF - IDrugs : the investigational drugs journal

SN - 1369-7056

IS - 5

ER -